Stock AnalizSarepta Therapeutics, Inc. SRPT
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Sarepta Therapeutics, Inc. (SRPT) is a healthcare company listed in the US with a market value of about $1.7B. In the twelve months to September 30, 2026 it had revenue of $2.0B and net income of -$115M, a net margin of -5.9%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is shareholder returns (0/5).
Key numbers: a price to free cash flow of 9.8, 5-year revenue growth of 32% a year, a 5-year average ROIC of -16%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 88% below the current price.
Score: 1.2 / 5
Checks passed
- P/FCF below 20
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Positive free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0B | $2.2B | $1.9B | $1.2B | $933M | $702M | $540M | $381M | $301M | $155M | $5M |
| Net income | -$115M | -$713M | $235M | -$536M | -$703M | -$419M | -$554M | -$715M | -$362M | -$51M | -$267M |
| Free cash flow | $176M | -$307M | -$343M | -$577M | -$356M | -$482M | $25M | -$516M | -$450M | -$244M | -$251M |
| EPS (diluted) | $-1.37 | $-7.13 | $2.34 | $-5.80 | $-8.03 | $-5.15 | $-7.11 | $-9.71 | $-5.46 | $-0.86 | $-5.49 |
| Net margin | -5.9% | -32.5% | 12.4% | -43.1% | -75.4% | -59.7% | -102.6% | -187.8% | -120.2% | -32.8% | -4930.2% |
| ROIC | — | -25.4% | 6.9% | -9.4% | -21.2% | -29.7% | -51.6% | -63.8% | -22.7% | -11.1% | -59.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 22 analysts is $21.77, 35% above the current price; targets range from $5.00 to $38.00; the consensus rating is “Hold”; expected EPS is $3.85 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Sarepta Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 88% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Sarepta Therapeutics pay a dividend?
Not currently.
Is Sarepta Therapeutics a good stock to buy?
We do not give buy or sell advice. Sarepta Therapeutics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.